EUVIMEDEUVIMED entdecken
Open Access

SARS-CoV-2 nsp13 suppresses hepatitis B virus replication by targeting cccDNA transcription

Aixin Li, Kaitao Zhao iD, Yurong Duan, Bei Zhang, Yingcheng Zheng, Chengliang Zhu, Qiongrong Chen, Wen-Bo Liu, Lixia Hui, Yuchen Xia iD, Xiaoming Cheng iD

Journal of Virology · 2024

DOI: 10.1128/jvi.01042-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Aixin Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology and Hubei Province Key Laboratory of Allergy and Immunology, Institute of Medical Virology, TaiKang Medical School, …. Hauptthemen laut MEDLINE: Virus Replication, Hepatitis B virus, DNA, Circular, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities, Open Grant from the Pingyuan Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS-CoV-2 nonstructural protein 13 (nsp13) has been shown to selectively suppress the transcription of episomal DNA while sparing chromosomal DNA. Hepatitis B Virus (HBV) harbors covalently closed circular DNA (cccDNA), a form of viral episomal DNA found within infected hepatocyte nuclei. The persistence of cccDNA is the major cause of chronic HBV infection. In this study, we investigated the impact of SARS-CoV-2 nsp13 on HBV replication, particularly in the context of cccDNA. Our findings demonstrate that nsp13 effectively hinders HBV replication by suppressing the transcription of HBV cccDNA, both in vitro and in vivo . Additionally, we observed that SARS-CoV-2 nsp13 binds to HBV cccDNA and its NTPase and helicase activities contribute significantly to inhibiting HBV replication. Furthermore, our screening identified the interaction between nsp13 and structural maintenance of chromosomes 4, opening new avenues for future mechanistic inquiries. This study presents the evidence suggesting the potential utilization of SARS-CoV-2 nsp13 as a strategy to impede HBV replication by specifically targeting cccDNA. These findings provide a proof of concept for exploring nsp13 as a prospective approach in combating HBV infection. IMPORTANCE To effectively combat hepatitis B virus (HBV), it is imperative to develop potent antiviral medications targeting covalently closed circular DNA (cccDNA). Our investigation aimed to assess the impact of SARS-CoV-2 nsp13 on HBV replication across diverse HBV models, confirming its ability to significantly reduce several HBV replication markers. Additionally, our identification of the interaction between nsp13 and SMC4 opens the door for further mechanistic exploration. This marks a paradigm shift in our approach to HBV antiviral therapy, introducing an entirely novel perspective. Our findings propose a novel strategy for developing anti-HBV drugs that specifically target HBV cccDNA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus ReplicationHepatitis B virusDNA, CircularSARS-CoV-2DNA, ViralHumansViral Nonstructural ProteinsHep G2 CellsAnimalsAntiviral AgentsCOVID-19Viral TranscriptionMiceTranscription, GeneticMethyltransferasesRNA Helicases

Stichwörter der Autor:innen

cccDNAhepatitis B virusnsp13transcriptional repression

Substanzen

DNA, CircularDNA, ViralViral Nonstructural ProteinsNsp13 protein, SARS-CoVAntiviral AgentsMethyltransferasesRNA Helicases

Autor:innen und Institutionen

  • State Key Laboratory of Virology and Hubei Province Key Laboratory of Allergy and Immunology, Institute of Medical Virology, TaiKang Medical School, Wuhan University, Wuhan, China.
  • School of Medical Laboratory, Shandong Second Medical University, Weifang, China.
  • School of Life Sciences, Hubei University, Wuhan, China.
  • Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
  • Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, Chile.
  • College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei, China.

ORCID-Profile: Kaitao Zhao, Yuchen Xia, Xiaoming Cheng

Förderung

  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities
  • Open Grant from the Pingyuan Laboratory
  • National Natural Science Foundation of China

Zitieren

APA

Li, A., Zhao, K., Duan, Y., Zhang, B., Zheng, Y., Zhu, C., Chen, Q., Liu, W. B., Hui, L., Xia, Y., & Cheng, X. (2024). SARS-CoV-2 nsp13 suppresses hepatitis B virus replication by targeting cccDNA transcription. Journal of Virology. https://doi.org/10.1128/jvi.01042-24

Vancouver

Li A, Zhao K, Duan Y, Zhang B, Zheng Y, Zhu C, et al. SARS-CoV-2 nsp13 suppresses hepatitis B virus replication by targeting cccDNA transcription. Journal of Virology. 2024. doi:10.1128/jvi.01042-24

BibTeX
@article{Li2024,
  author = {Li, Aixin and Zhao, Kaitao and Duan, Yurong and Zhang, Bei and Zheng, Yingcheng and Zhu, Chengliang and Chen, Qiongrong and Liu, Wen-Bo and Hui, Lixia and Xia, Yuchen and Cheng, Xiaoming},
  title = {SARS-CoV-2 nsp13 suppresses hepatitis B virus replication by targeting cccDNA transcription},
  journal = {Journal of Virology},
  year = {2024},
  doi = {10.1128/jvi.01042-24}
}
Kostenlos starten →